Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

1.125 -0.055 (-4.69%)

Streaming Delayed Price Updated: 1:18 PM EST, Jan 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	168,888
Open	1.168
Bid (Size)	1.120 (5,400)
Ask (Size)	1.130 (800)
Prev. Close	1.180
Today's Range	1.120 - 1.168
52wk Range	0.9657 - 9.790
Shares Outstanding	5,726,750
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

December 23, 2025

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. -...

Via Newsfile

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

November 25, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Performance

YTD	+3.2%	+3.2%
1 Month	+3.2%	+3.2%
3 Month	-49.3%	-49.3%
6 Month	-52.7%	-52.7%
1 Year	-83.0%	-83.0%

More News

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

November 17, 2025

Via Newsfile

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025

Via Newsfile

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

November 07, 2025

Via Newsfile

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

November 07, 2025

Via Newsfile

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

These stocks are the most active in today's session ↗

November 03, 2025

Via Chartmill

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

November 03, 2025

Via Newsfile

Why Is Phio Pharmaceuticals Stock Soaring Today? ↗

November 03, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

Via Chartmill

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

November 03, 2025

Via Newsfile

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

October 31, 2025

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

October 21, 2025

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

September 23, 2025

Via Newsfile

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

September 18, 2025

Via Newsfile

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

Via Newsfile

Phio Posts Wider Loss in Fiscal Q2 ↗

August 14, 2025

Via The Motley Fool

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

Via Newsfile

Frequently Asked Questions

Is Phio Pharmaceuticals Corp. - Common Stock publicly traded?

Yes, Phio Pharmaceuticals Corp. - Common Stock is publicly traded.

What exchange does Phio Pharmaceuticals Corp. - Common Stock trade on?

Phio Pharmaceuticals Corp. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Phio Pharmaceuticals Corp. - Common Stock?

The ticker symbol for Phio Pharmaceuticals Corp. - Common Stock is PHIO on the Nasdaq Stock Market

What is the current price of Phio Pharmaceuticals Corp. - Common Stock?

The current price of Phio Pharmaceuticals Corp. - Common Stock is 1.125

When was Phio Pharmaceuticals Corp. - Common Stock last traded?

The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 01/14/26 01:18 PM ET

What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?

The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 6.44M

How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?

Phio Pharmaceuticals Corp. - Common Stock has 6M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.